TRENTON, N.J. (AP) — A generic drugmaker plans to start selling a slightly cheaper version of the EpiPen in the U.S. early next year.
The penlike injectors are used to treat life-threatening allergic reactions. Brand-name EpiPen, which dominates the market, has been in short supply since spring because of production problems.
Drugmaker Sandoz said Thursday the price of two generic injectors will be $250 without insurance. Two other generics on the market in the U.S. cost $300 a pair. Brand-name EpiPens sold by Mylan cost at least twice as much.
The price people pay varies, though, depending on insurance and discounts.
Mylan was blasted in the past for price hikes that pushed the price over $600. It responded by selling its own generic.
- Drugmaker to sell cheaper generic rival to EpiPen injectors
- US approves new generic competitor to EpiPen
- FDA anticipates EpiPen shortage
- Lilly to sell cheaper version of top-selling insulin Humalog
- FDA extends some EpiPen expiration dates due to shortage
- Senate candidate writes children’s book trashing GOP rival
- Botswana unveils blue diamond to rival the Hope Diamond
- Netflix faces a new rival in the UK
- Backpack Program receives generous donation
- Loogootee Library receives generous donation